Pharmaceuticals News

First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal...

Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens...

ELLON, United Kingdom, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Scottish craft brewer BrewDog, by Tilray Brands, Inc., today unveiled its 2026 Advent Calendar, a 24-day countdown bringing together...

General Oncology nominated for 2026 Prix Galien USA Award for Best Startup, after preliminary Phase 1 results for GO-4 in BRCA-mutated pancreatic cancer.

As a global medical cannabis leader, Tilray Medical supports continued policy development that strengthens physician confidence, protects patient access and provides a clear, sustainable framework for...

Als weltweit führender Anbieter von medizinischem Cannabis unterstützt Tilray Medical eine Weiterentwicklung der Regulierung, die das Vertrauen der Ärzteschaft stärkt, den Zugang der Patienten schützt...

Asimov will use its CHO Edge System to develop a high-titer cell line for Kaigene’s therapeutic candidate that selectively degrades pathogenic antibodies.

Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS...

PRESS RELEASE CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor LONDON – 18 August 2026 -- CHARM Therapeutics...

Company announcement no. 31 - 2618 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...